Anlotinib Reverses Multidrug Resistance (MDR) in Osteosarcoma by Inhibiting P-Glycoprotein (PGP1) Function In Vitro and In Vivo

• Main Authors: Gangyang Wang (Author), Lingling Cao (Author), Yafei Jiang (Author), Tao Zhang (Author), Hongsheng Wang (Author), Zhuoying Wang (Author), Jing Xu (Author), Min Mao (Author), Yingqi Hua (Author), Zhengdong Cai (Author), Xiaojun Ma (Author), Shuo Hu (Author), Chenghao Zhou (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Overexpression of the multidrug resistance (MDR)-related protein P-glycoprotein (PGP1), which actively extrudes chemotherapeutic agents from cells and significantly decreases the efficacy of chemotherapy, is viewed as a major obstacle in osteosarcoma chemotherapy. Anlotinib, a novel tyrosine kinase...